A Personalised Percutaneous External 3D Guide for Scaphoid Fixation
Launched by CORPORACION PARC TAULI · Apr 11, 2018
Trial Information
Current as of May 23, 2025
Unknown status
Keywords
ClinConnect Summary
To carry out this analysis the investigators will recruit 10 patients who present with an acute fracture of the Scaphoid bone type B1 and B2 (Herbert Classification).
A CT Scan will be performed and a 3D exoesqueleton model printed, previously deciding the position of the fixation screw inside of the bone and adding a cannulated sleeve in the volar aspect of the exoesqueleton to insert the initial positional guide wire for surgery.
Surgery time, surgery radiation exposure and screw positioning will be recorded and compared to 10 control patients operated following standard procedure.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Acute scaphoid fracture (Herbert B1 B2)
- Exclusion Criteria:
- • Concomitant fractures
About Corporacion Parc Tauli
Corporación Parc Taulí is a leading healthcare organization based in Sabadell, Spain, known for its commitment to advancing medical research and clinical excellence. With a focus on innovative healthcare solutions, the organization integrates cutting-edge technology and multidisciplinary collaboration to enhance patient outcomes. As a sponsor of clinical trials, Corporación Parc Taulí emphasizes ethical practices, rigorous scientific methodologies, and robust data management to contribute to the development of new therapies and improve healthcare standards. Their dedication to research and patient care positions them as a vital player in the clinical research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sabadell, Barcelona, Spain
Patients applied
Trial Officials
Francesc A Marcano Fernandez, MD
Principal Investigator
Hospital parc tauli Sabadell
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials